Comparison of the actions of carbamate anticholinesterases on the nicotinic acetylcholine receptor.
Neostigmine (Neo), pyridostigmine (Pyr), and physostigmine (Phy) at low concentrations inhibited acetylcholine (ACh) esterase, thereby indirectly potentiating ACh enhancement of [3H]perhydrohistrionicotoxin (H12-HTX) binding to the channel sites of the nicotinic ACh receptor of Torpedo membranes. However, at higher concentrations, they inhibited ACh action due to their direct binding to the ACh receptor. They displaced binding of [3H]ACh and 125I-alpha-bungarotoxin (alpha-BGT) to the receptor sites with the following order of decreasing potency: Neo greater than Phy greater than Pyr. Furthermore, Neo and Pyr potentiated [3H] H12-HTX binding to the receptor's channel sites. Preincubation of ACh receptors with any of the three carbamates reduced the rate of binding of 125I-alpha-BGT and increased the potency of carbamylcholine in inhibiting 125I-alpha-BGT binding, suggesting that the three carbamates act as partial agonists and potentiate receptor desensitization. Although none of the three carbamates inhibited [3H]H12-HTX binding to the receptor's closed channel conformation, only Phy was a potent inhibitor of [3H]H12-HTX binding to the carbamylcholine-activated conformation. The potency of Phy was not due to the absence of positive charge since Phy methiodide acted similarly. The data suggest that the major action of the three carbamates at nicotinic cholinergic synapses is inhibition of ACh-esterase. Their interactions with the nicotinic ACh receptor are with its "receptor" as well as allosteric "channel" sites, but they differ in their effects. Neo and Pyr act mainly as partial agonists, while Phy is mostly an inhibitor of the channel in the activated receptor conformation.
D000109:Acetylcholine / Q000378:metabolism; D000664:Amphibian Venoms / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive; D002038:Bungarotoxins / Q000378:metabolism; D002217:Carbachol / Q000494:pharmacology; D004557:Electric Organ / Q000187:drug effects; D007700:Kinetics; D009388:Neostigmine / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology*; D011729:Pyridostigmine Bromide / Q000494:pharmacology*; D011950:Receptors, Cholinergic / Q000378:metabolism*; D014101:Torpedo
D000664:Amphibian Venoms; D002038:Bungarotoxins; D011950:Receptors, Cholinergic; D009388:Neostigmine; C004792:perhydrohistrionicotoxin; D002217:Carbachol; D010830:Physostigmine; D011729:Pyridostigmine Bromide; D000109:Acetylcholine